Home Competition

Competition

Competitive Position — Centene Corporation (CNC)

Competitive Bottom Line

Centene has the largest Medicaid footprint and leads the ACA Marketplace, but its FY2025 loss exposed a commodity position in rate-sensitive government programs. The moat is operational scale and state relationships, not pricing power or product differentiation. UnitedHealth Group (UNH) is the primary threat — its Optum vertical integration creates cost advantages and data leverage that pure MCOs like Centene cannot match. Centene's investability hinges on whether it can reprice 2026 books faster than medical cost accelerates and whether OBBBA work requirements erode its Medicaid base.

The Right Peer Set

These five peers represent the competitive field for Centene's government-programs-heavy model. UNH sets the scale benchmark. ELV and CI are diversified MCOs with commercial exposure. HUM is the pure Medicare Advantage benchmark. MOH is the cleanest pure-play government-programs comp.
No Results

All peers are public US companies reporting in USD. Market cap and enterprise value sourced from Fiscal.ai ratios.json at FY2025 close. Centene's EV is N/A because FY2025 net income was negative, rendering net-debt calculations non-comparable. CNC's market cap has since rerated to ~$29B at $58.81 in May 2026; peer multiples on this table reflect the FY25-close snapshot for consistency.

Where The Company Wins

Centene's advantages are scale in rate-constrained segments and operational efficiency:

  1. #1 Medicaid position (12.5M members at FY25-end, 30 states) — largest footprint among public MCOs. State relationships and provider networks create renewal inertia. Source: CNC FY2025 release, peer comparison in industry-grok.md.

  2. #1 ACA Marketplace carrier (5.5M members at FY25-end, 3.58M at Q1 FY26-end after the post-APTC contraction, 29 states) — Ambetter brand has scale advantages in marketing, risk adjustment, and network contracting. Rate filings approved for states covering ~95% of 2026 membership. Source: Q1 FY26 earnings release; Q3 FY25 transcript.

  3. #1 stand-alone PDP franchise (8.1M members FY25-end, ~8.7M Q1 FY26) — Part D scale provides leverage with PBMs and pharmacies. Source: CNC FY2025 release and Q1 FY26 transcript.

  4. Low SG&A ratio (7.6% in Q1 FY26) — near the low end of peers, reflecting scale and technology investment. Source: Q1 FY26 earnings release, peer SG&A benchmarking in industry-grok.md.
No Results

Where Competitors Are Better

  1. UNH vertical integration (Optum) — Optum provides PBM, care delivery, and data analytics that reduce medical cost and improve risk adjustment. Centene lacks equivalent capability. UNH's 2025 operating margin was 4.24% vs. CNC's -3.91%. Source: FY2025 income.json for both companies.

  2. UNH and ELV commercial mix — Commercial group business has higher margins and less regulatory risk than Medicaid/Marketplace. UNH and ELV derive a larger share of revenue from commercial/group than CNC does. Source: peer business.txt files, industry-grok.md segment breakdown.

  3. HUM Medicare Advantage depth — HUM's CenterWell clinics and MA-focused model give it better Star-rating performance and MA margin visibility. HUM's MA book runs HBR in the low-to-mid 80s vs. CNC's higher-acuity mix. Source: HUM business.txt, CNC vs. HUM HBR comparison in industry-grok.md.

  4. CI Evernorth PBM scale — Cigna's PBM and services business (Evernorth) provides a high-margin, capital-light revenue stream that CNC's Envolve specialty pharmacy lacks. CI's P/E of 12.41x reflects this diversification premium vs. CNC's loss-making multiple. Source: CI business.txt, peer_valuations.json.

Threat Map
No Results

Moat Watchpoints

These five signals determine whether Centene's competitive position is improving or eroding:

  1. Consolidated HBR vs. priced HBR — Quarterly press release + 10-Q segment HBR. If actual HBR runs hotter than priced, the moat is eroding. Q1 FY26 consolidated HBR landed at 87.3% and Medicaid HBR improved 50 bp YoY to 93.1%; watch Q2-Q4 for confirmation.

  2. Medicaid composite rate yield (PMPM growth) — Earnings call commentary. CNC guided ~4.5% for 2026. If rates come in below 4% while medical cost trend stays above 5%, margin pressure returns.

  3. Marketplace risk adjustment accrual (Wakely data) — Quarterly segment commentary + actuarial filings. Full accrual recognition signals the 2026 repricing captured the morbidity shift. Partial accrual = under-pricing risk.

  4. Medicare Star ratings (October CMS release) — Share of members in 4.0+ Star contracts. A drop below 3 Stars on any contract risks termination and bonus loss. HUM and UNH have historically outperformed CNC on Stars.

  5. OBBBA implementation by state (2027+) — State Medicaid agency notices and CMS sub-regulatory guidance. States with work requirements that see high disenrollment without rate true-up will pressure CNC's largest segment. Watch for rate offsets in leaner states.

Manifest: This tab covers UNH, ELV, HUM, MOH, CI. All public peers have market cap and enterprise value from Fiscal.ai FY2025 ratios. Private, subsidiary-only, or delisted entities are N/A (none in peer set). Data sources: peer_set.json, peer_valuations.json, evidence_manifest.json, competitor snapshot.json / income.json / business.txt files, industry-grok.md. No Parallel Task or FindAll calls used — peer boundary was well-defined.